Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur publishes positive efficacy data for dengue vaccine

Sanofi Pasteur publishes positive efficacy data for dengue vaccine

11th July 2014

Sanofi Pasteur has announced the publication of phase III trial data that supports the safety and efficacy of its innovative new vaccine candidate for dengue fever.

Appearing in the latest issue of the Lancet, results from the landmark phase III dengue vaccine efficacy study – conducted in five countries in Asia – showed overall efficacy against symptomatic dengue of 56.5 percent in children aged two to 14 after a three-dose schedule.

Moreover, further analyses show an 88.5 percent reduction in dengue haemorrhagic fever, the severe form of dengue, and a clinically important reduction in the risk of hospitalisation due to dengue by 67 percent.

Dengue threatens the health of nearly half the world's population, particularly those in Asia and Latin America. This is the first vaccine candidate to show efficacy in a phase III study.

John Shiver, senior vice-president for research and development at Sanofi Pasteur, said: "These pivotal phase III vaccine efficacy study results take us closer to our ambition to bring the first vaccine against dengue to the world."

This comes in the same week that the company agreed a new licensing deal with CureVac for the development of a mRNA-based prophylactic vaccine.ADNFCR-8000103-ID-801734696-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.